Recently, PET radiotracers targeting prostate-specific membrane antigen (PSMA), labeled with either 68Ga or 18F, have demonstrated favorable results for imaging men with prostate cancer (PCa) in a variety of clinical contexts [1–3]. This evidence concerns the gene FOLH1 and prostate cancer.